General Information of Drug (ID: DMTK1BV)

Drug Name
SRF617 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMTK1BV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
IPH5201 DMFEI6T Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
TTX-030 DM8H2AG Lymphoma 2A80-2A86 Phase 1 [4]
PSB-0963 DMBDVJ1 Discovery agent N.A. Investigative [5]
PSB-6426 DMJ9ML8 Discovery agent N.A. Investigative [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) TTYM8DJ ENTP1_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT04336098) Study of SRF617 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Surface oncology.
3 ClinicalTrials.gov (NCT04261075) IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.. U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of AbbVie.
5 Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.
6 Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5'-carboxamide. J Med Chem. 2008 Aug 14;51(15):4518-28.